48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Item
http://www.wikidata.org/entity/Q34134900
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVAn Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyPatient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland.Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Dual antiretroviral therapy for HIV infection.Abacavir + dolutegravir + lamivudine for the treatment of HIV.Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical triHigher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.Severe depression as a neuropsychiatric side effect induced by dolutegravir.
P2860

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Item
http://www.wikidata.org/entity/Q34134900
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
48-week efficacy and safety of ...... iew and network meta-analysis.
@ast
48-week efficacy and safety of ...... iew and network meta-analysis.
@en
48-week efficacy and safety of ...... iew and network meta-analysis.
@nl
type
label
48-week efficacy and safety of ...... iew and network meta-analysis.
@ast
48-week efficacy and safety of ...... iew and network meta-analysis.
@en
48-week efficacy and safety of ...... iew and network meta-analysis.
@nl
prefLabel
48-week efficacy and safety of ...... iew and network meta-analysis.
@ast
48-week efficacy and safety of ...... iew and network meta-analysis.
@en
48-week efficacy and safety of ...... iew and network meta-analysis.
@nl
P1433
P1476
P2093
P275
P2860
P304
P31
P356
P407
P433
P478
P5008
P577
P5875
P698
P921
P932
P356
P1433
P1476
48-week efficacy and safety of ...... iew and network meta-analysis.
@en
P2093
P275
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0105653
P407
P433
P478
P5008
P577
P5875
P698
P921
P932